Expand IOVA Menu
IOVA MENU

IOVA Latest Press Releases

-- March 20, 2026 --

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) Globe Newswire 5:15 PM

-- February 26, 2026 --

Iovance Biotherapeutics to Present at Upcoming Conferences Globe Newswire 8:00 AM

-- February 24, 2026 --

Iovance Biotherapeutics Highlights Strong Fourth Quarter and Full Year 2025 Results, Business Achievements and Corporate Updates Globe Newswire 7:00 AM
Iovance Announces Positive Results from the First Clinical Trial for TIL Cell Therapy in Soft Tissue Sarcomas Globe Newswire 7:00 AM

-- February 20, 2026 --

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) Globe Newswire 5:15 PM

-- February 11, 2026 --

Iovance Biotherapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Corporate Updates on Tuesday, February 24, 2026 Globe Newswire 4:05 PM

-- February 5, 2026 --

Best-in-Class Real-World Data Support Early Amtagvi Treatment in Advanced Melanoma Globe Newswire 5:15 PM

-- January 16, 2026 --

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) Globe Newswire 5:15 PM

-- January 12, 2026 --

Johnson Fistel, PLLP Investigates Claims on Behalf of Long-Term Shareholders of Iovance Biotherapeutics, Inc. (IOVA), Nutex Health, Inc. (NUTX), Lantheus Holdings, Inc. (LNTH), and Molina Healthcare, Inc. (MOH) Globe Newswire 3:31 PM

-- December 19, 2025 --

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) Globe Newswire 5:15 PM

-- November 24, 2025 --

Biotech Valuations Rise as New Clinical Platforms Show Progress Globe Newswire 8:30 AM

-- November 21, 2025 --

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) Globe Newswire 5:15 PM
Market Data Delayed 15 Minutes